The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR tyrosine kinase inhibitor (TKI)-responsive, non-small cell lung cancer (NSCLC) that subsequently progresses.
Balazs Halmos
Research Funding - Astellas Pharma; Astex Therapeutics; Boehringer Ingelheim; Daiichi Sankyo; Lilly; Oncothyreon; Pfizer; Sanofi
Nathan A. Pennell
Research Funding - Oncogenex; Teva
Gregory Alan Otterson
Consultant or Advisory Role - Boehringer Ingelheim; Genentech
Research Funding - Boehringer Ingelheim; Genentech; GlaxoSmithKline; Pfizer; Synta; Tragara Pharmaceuticals
Shirish M. Gadgeel
No relevant relationships to disclose
Tarek Mekhail
Honoraria - Genentech; Lilly
Michael Robert Snell
No relevant relationships to disclose
J. Phillip Kuebler
No relevant relationships to disclose
Pingfu Fu
No relevant relationships to disclose
Neelesh Sharma
No relevant relationships to disclose
Afshin Dowlati
Consultant or Advisory Role - Millennium
Honoraria - Genentech
Research Funding - Amgen; Bristol-Myers Squibb; Genentech; ImClone Systems; Sanofi